SIETES :: 92610 citas

Resultados de la búsqueda por EVALUACIÓN REFINAR BÚSQUEDA

1.

Mershon E. STAT Plus: It’s not over: After defeat on ‘right to try,’ GOP vows to renew push. STAT Daily Recap 2018:2. [Ref.ID 102468]

2.

Harrington M, Sigal EV. Opinion: ‘Right-to-try’ law threatens patient safety and rational drug development. STAT Daily Recap 2018:6. [Ref.ID 102467]

3.

Anónimo. Spain hiring more staff at national drug agency to prepare for Brexit disruption. DIA Daily 2017:5. [Ref.ID 102043]

4.

Hampp C, Pippins J. Pioglitazone and bladder cancer: FDA's assessment. Pharmacoepidemiol Drug Saf 2017;26:117-8. [Ref.ID 101950]

5.

Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med 2016;375:65-74. [Ref.ID 100614]

6.

Solans-Domènech M, Permanyer-Miralda G. Evaluación del impacto de la investigación biomédica: ¿para quién?. Med Clin (Barc) 2016;146:491-3. [Ref.ID 100373]

7.

Anónimo. FDA staff raise questions about Sanofi’s diabetes combination treatment. DIA Daily 2016:2. [Ref.ID 100300]

8.

Stafford N. German drug industry says pricing law is restricting access to some drugs. BMJ 2015;351:h6205. [Ref.ID 99692]

9.

Maynard A, Bloor K. Regulation of the pharmaceutical industry: promoting health or protecting wealth?. J R Soc Med 2015;108:220-2. [Ref.ID 99099]

10.

Köhler M, Haag S, Biester K, Brockhaus AC, McGauran N, Grouven U, Kölsch H, Seay U, Hörn H, Moritz G, Staeck K, Wieseler B. Information on new drugs at market entry: retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports. BMJ 2015;350:h796. [Ref.ID 98850]

11.

Doshi P, Jefferson T. The evidence base for new drugs. BMJ 2015;350:h952. [Ref.ID 98849]

12.

13.

Mäkelä KT, Matilainen M, Pulkkinen P, Fenstad AM, Havelin L, Engesaeter L, Furnes O, Pederson AB, Overgaard S, Kärrholm J, Malchau H, Garellick G, Ranstam J, Eskelinen A. Failure rate of cemented and uncemented total hip replacements: register study of combined Nordic database of four nations. BMJ 2014;348:14. [Ref.ID 97252]

14.

Hamilton DF, Howie CR. Selecting the right hip replacement. BMJ 2014;348:g46. [Ref.ID 97250]

15.

Iannone P, Haupt E, Flego G, Truglio P, Minardi M, Clarke S, Magrini N. Dronedarone for atrial fibrillation: the limited reliability of clinical practice guidelines. JAMA Intern Med 2014;174:625-9. [Ref.ID 97190]

16.

Anónimo. Drug assessment: UK style. Drug Ther Bull 2013;51:141-4. [Ref.ID 96627]

17.

Smith MEB, Totten A, Hickam DH, Fu R, Wasson N, Rahman B, Motu'apuaka M, Saha S. Pressure ulcer treatment strategies: a sytematic comparative effectiveness review. Ann Intern Med 2013;159:39-50. [Ref.ID 95856]

18.

Chou R, Dana T, Bougatsos C, Blazina I, Starmer AJ, Reitel K, Buckley DI. Pressure ulcer risk assessment and prevention: a systematic comparative effectiveness review. Ann Intern Med 2013;159:28-38. [Ref.ID 95855]

19.

20.

Toussaint B. EU clinical trial regulation. Lancet 2013;381:1719-20. [Ref.ID 95444]